Deals this week: Atreca, Calithera Biosciences, Spring Bank Pharmaceuticals
US-based biotechnology company Atreca has secured $35m in a series B financing round led by Wellington Management Company.
The funds will be utilised to progress the development of the company’s antibody-based therapeutics.
Calithera Biosciences has announced a public offering of common stock shares to raise up to $50m.
The US-based clinical-stage pharmaceutical company plans to use the funds towards general corporate purposes.
Spring Bank Pharmaceuticals plans to raise up to $50m through a public offering of shares of its common stock.
US-based clinical-stage biopharmaceutical company Spring Bank plans to use the proceeds for general corporate purposes.
Coherus BioSciences (formerly known as BioGenerics) has announced the private placement of six million shares of its common stock priced at $11.44 a share to raise $75m.
The company intends to raise a total of $150m in two tranches, with $75m to be raised in the first tranche.
The US-based biopharmaceutical company plans to use the funds towards the development of its pegfilgrastim biosimilar product candidate CHS-1701, as well as general corporate purposes.